HMAI white logo
President’s letter
2020 Metrics
Cycle of Translation
Visionary Gifts
triangle_down.svg
Discovery to Clinic
triangle_down.svg
Innovative Education
triangle_down.svg
Translational Luminaries
Close_Menu.svgSearch.svg
triangle_down.svg
result
Science in Service
of
Medicine
result
President's letter
2020 Metrics
Cycle of Translation
From Discovery to Clinic
Down_arrow.svg
Up_arrow.svg
Translational Luminaries
Close_menu.svg
Discovery to Clinic
Restorative Medicine
Revolutionizing the Future of Complex Valve Disease Management
Revolutionizing the Future of Complex Valve Disease Management
Share this story
Replacing a faulty aortic valve once required open-heart surgery, which can pose significant risks for patients who are older or have certain comorbidities. The advent of minimally invasive transcatheter aortic valve replacement, or TAVR, procedure, where the replacement valve is inserted via a small incision in the groin or chest, has opened much needed treatment options for these patients.
“Momentous breakthroughs don’t happen often in medicine, TAVR is certainly one of the most exciting developments in recent times,” said Michael J. Reardon, MD, Allison Family Distinguished Chair of Cardiovascular Research in the department of cardiovascular surgery. “The Houston Methodist DeBakey Heart & Vascular Center’s valve clinic team has been at the very forefront of this pioneering innovation in minimally invasive surgery, making Houston Methodist one of the most experienced TAVR sites in the nation.” Under the leadership of Reardon and his cardiology partner Lois and Carl Davis Centennial Chair, Neal Kleiman, MD, the TAVR program has contributed to hundreds of publications in recent years and has played a key role in shaping this new field.
“TAVR is a force of positive disruption that is completely redefining the scope of valve replacement surgery. With the expanded indication, TAVR will be a game-changer for low-risk patients who are seeking to avoid the risks and longer recovery associated with surgery.”
– Michael J. Reardon, MD
Allison Family Distinguished Chair of Cardiovascular Research Department of Cardiovascular Surgery Houston Methodist
TAVR was initially approved by the FDA for use in patients with an intermediate or high risk of death or major complications during open-heart surgery. In August 2019, the FDA expanded approval to low-risk patients based on outcomes from two landmark clinical trials, Reardon was the national principal investigator for one of the trials. It confirmed that TAVR was a safe and effective treatment option for low-risk patients and was associated with shorter hospital stays, improved quality-of-life scores and a significantly lower rate of all-cause mortality or disabling stroke compared to traditional surgery. The complete findings are published in The New England Journal of Medicine.
Share this story